ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2014
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Cost-effectiveness of lung cancer screening: insights from risk stratification, guidelines, and emerging technologies-a systematic review.NPJ primary care respiratory medicine · 2026Pooled it
- Surgical Aspects of Treatment of the Lung Cancer Found in Low-Dose CT-Based Screenings.Journal of clinical medicine · 2026Article
- Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024Review
- The Smokers Health Multiple ACtions (SMAC-1) Trial: Study Design and Results of the Baseline Round.Cancers · 2024Article
- Health Care Utilization and Costs in Lung Cancer Screening Participants-A Propensity-Matched Economic Analysis.JTO clinical and research reports · 2023Article
- Lung cancer screening an asbestos exposed population: Existing lung cancer risk criteria are not sufficient.Respirology (Carlton, Vic.) · 2023Article
- Survival and medical costs of non-small cell lung cancer patients according to the first-line treatment: An observational study using the Kyoto City Integrated Database.Thoracic cancer · 2023Observational
- Priorities among effective clinical preventive services in British Columbia, Canada.BMC health services research · 2022Article
- Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology.Current oncology (Toronto, Ont.) · 2022Review
- Lung cancer screening: who pays? Who receives? The European perspectives.Translational lung cancer research · 2021Review
- Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe.Cancers · 2020Review
- Protocol and Rationale for the International Lung Screening Trial.Annals of the American Thoracic Society · 2020Article
- Magnetic Resonance Spectroscopy-based Metabolomic Biomarkers for Typing, Staging, and Survival Estimation of Early-Stage Human Lung Cancer.Scientific reports · 2019Article
- Current Practice in the Management of Pulmonary Nodules Detected on Computed Tomography Chest Scans.Canadian respiratory journal · 2019Article
- Pathways and cost-effectiveness of routine lung cancer inpatient care in rural Anhui, China: a retrospective cohort study protocol.BMJ open · 2018Article
- Editorial on PanCan study.Translational lung cancer research · 2018Article
- Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.European radiology · 2017Article
- Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers.PloS one · 2017Article
- Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.Current oncology (Toronto, Ont.) · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 18 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs.
methodsResource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study.
resultsThe average per-person cost for screening individuals with LDCT was $453 (95% confidence interval [CI], $400-$505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was $33,344 (95% CI, $31,553-$34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% CI, $43,254-$52,200; p = 0.061).
conclusionIn the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.